Objective To investigate the clinical effect of Qingrelishi prescription in the treatment of infantile rotavirus enteritis (RE). Methods One hundred and twenty children with RE admitted to the Department of Intestinal Outpatient of Tianjin Children's Hospital from October to November 2018 were enrolled, and they were divided into a Qingrelishi prescription group and a western medicine treatment control group, 60 cases in each group. Qingrelishi prescription addition and/or subtraction was given to the Qingrelishi prescription group (composition of the prescription: pueraria lobata, radix pseudostellariae, poria cocos, fried atractylodes macrocephala, each 6 g, scutellaria baicalensis, coptis chinensis, amomum villosum, argastaches leaves, roasted licorice, each 3 g), 1 dose a day, orally taken 1/2 dose twice a day, in thermogravimetric patients, plaster and rhizoma phragmititis were added, in cases with dampness, rhizoma alismatis and rhizoma atractylodis were added, and in patients with vomiting, bamboo shavings and pinellia were added; the western medicine treatment control group was given Montmorillonite powder. After 7 days of treatment, the clinical symptoms, changes of laboratory indexes and clinical efficacy were observed in both groups. Results After treatment, the number of children with stool soft, cases with fecal times less than 3 times per day and cases with reduction of fecal times ≥ 50% in Qingrelishi prescription group were obviously more than those in the western medicine treatment control group (fecal property soft: 25 cases vs. 21 cases, fecal times less than 3 times per day: 28 cases vs. 22 cases, cases with reduction of fecal times ≥ 50%: 48 cases vs. 41 cases, all P < 0.05). The number of children with laboratory examination index of rotavirus antigen (RV-Ag) transformed into negative, the case number with pH value normal shown by blood gas analysis, cases with residual alkali (BE) normal and cases with urinary ketone body transformed into negative in the Qingrelishi prescription group were significantly higher than those in western medicine treatment control group (RV-Ag transformed into negative cases: 49 cases vs. 42 cases, pH value normal cases:48 cases vs. 42 cases, BE normal cases: 51 cases vs. 43 cases, urinary ketone body transformed into negative cases:52 cases vs. 44 cases, all P < 0.05). The total effective rate of Qingrelishi prescription group was significantly higher than that of the western medicine treatment control group [80.0% (48/60) vs. 68.33% (41/60)], the difference was statistically significantly (P < 0.05). Conclusion Qingrelishi prescription can significantly improve the clinical symptoms and laboratory examination indicators of children with RE, increase the total clinical efficacy, and its therapeutic effect is definite.%目的 观察清热利湿方治疗小儿轮状病毒肠炎(RE)的临床疗效.方法 选择2018年10月至11月在天津市儿童医院肠道门诊就诊的RE患儿120例,按治疗方法不同将患儿分为清热利湿方组和西医治疗对照组,每组60例.清热利湿方组给予清热利湿方加减(组成:葛根、太子参、茯苓、炒白术各6 g,黄芩、黄连、砂仁、藿香叶、炙甘草各3 g),热重者加石膏、芦根,湿重者加泽泻、苍术,呕吐者加竹茹、半夏,每日1剂、每日2次;西医治疗对照组给予蒙脱石散.两组均治疗7 d后观察临床症状、实验室检查指标的变化及临床疗效.结果 清热利湿方组治疗后粪便性质呈软便、每日排便次数＜3次、排便次数减少≥50%的例数均明显多于西医治疗对照组(粪便性质呈软便:25例比21例,每日排便次数＜3次:28例比22例,排便次数减少≥50% :48例比41例,均P＜0.05).实验室检查指标轮状病毒抗原(RV-Ag)转阴性例数和血气分析显示pH值正常例数、剩余碱(BE)正常例数、尿酮体转阴例数均明显多于西医治疗对照组(RV-Ag转阴:49例比42例,pH值正常:48例比42例,BE正常:51例比43例,尿酮体转阴:52例比44例,均P＜0.05).清热利湿方组总有效率明显高于西医治疗对照组〔80.0%(48/60)比68.33%(41/60)〕,差异有统计学意义(P＜0.05).结论 清热利湿方可明显改善RE患儿临床症状及实验室检查指标,提高临床总有效率,疗效确切.
展开▼
